

ORIGINAL ARTICLE

One-year recurrence rate of new-onset atrial fibrillation after acute myocardial infarction



Alicia Prieto-Lobato^{a,*}, Víctor Hidalgo Olivares^a, Manuel Gerónimo Pardo^b,
 Marta Cubells Pastor^a, Francisco Manuel Salmerón Martínez^a,
 Miguel José Corbí-Pascual^a

^a Cardiology Department at Hospital General de Albacete, Albacete, Spain

^b Anesthesiology Department at Hospital General de Albacete, Albacete, Spain

Received 31 July 2024; accepted 9 December 2024

Available online 19 May 2025

KEYWORDS

Atrial fibrillation;
 Myocardial infarction;
 Heart failure;
 Prognosis

Abstract

Introduction and objectives: Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide, with a prevalence of up to 21% in the early phase of acute myocardial infarction (AMI). Data on new-onset AF in this context are limited, and long-term prognosis remains unclear.

Methods: We conducted a retrospective observational cohort study from December 2011 to May 2021, including patients who experienced a first episode of paroxysmal AF during hospitalization for AMI. The primary outcome was the recurrence of AF within the first year post-discharge. Secondary outcomes included all-cause mortality, cardiovascular mortality, and a composite of major adverse cardiovascular events.

Results: A total of 209 patients were included. There was AF recurrence in 19 patients, 9.1% (95% CI 5.2–13.0%) with a median time to recurrence of 84 days (interquartile range 27.5–157.5). While mortality in the AF recurrence group was numerically higher than in the non-AF recurrence group, this difference did not achieve statistical significance (15.8% vs. 7.4%, $p=0.19$). Patients with AF recurrence had significantly worse prognosis (47.4% vs. 23.7%, $p=0.04$), primarily due to increased heart failure (HF) hospitalizations.

Conclusions: In patients with a first episode of paroxysmal AF during AMI, one-year recurrence is relatively low (9.1%); however, AF recurrence is associated with significantly worse prognosis, driven largely by HF hospitalizations.

© 2025 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: alicia.prieto.lobato@psmar.cat (A. Prieto-Lobato).

PALAVRAS-CHAVE

Fibrilhação auricular;
Enfarte agudo do
miocárdio;
Insuficiência
cardíaca;
Prognóstico

Taxa de recorrência num ano de fibrilhação auricular de novo após enfarte agudo do miocárdio**Resumo**

Introdução e objetivos: A fibrilhação auricular (FA) é a arritmia cardíaca mais comum a nível mundial, com uma prevalência de até 21% na fase inicial do enfarte agudo do miocárdio (EAM). Os dados relativos à FA de início recente neste contexto são limitados, e o seu prognóstico a longo prazo permanece incerto.

Métodos: Realizámos um estudo de coorte observacional retrospectivo entre dezembro de 2011 e maio de 2021, incluindo doentes que apresentaram um primeiro episódio de FA paroxística durante a hospitalização por EAM. O resultado primário foi a taxa de recorrência de FA no primeiro ano após a alta hospitalar. Os resultados secundários incluíram mortalidade por todas as causas, mortalidade cardiovascular e um composto de eventos cardiovasculares adversos maior.

Resultados: Um total de 209 doentes foi incluído. A recorrência de FA ocorreu em 19 doentes (9,1%, IC 95% 5,2-13,0%), com um tempo mediano até à recorrência de 84 dias [IQR 27,5-157,5]. Apesar da mortalidade no grupo com recorrência de FA ter sido numericamente superior à do grupo sem recorrência de FA, essa diferença não alcançou significância estatística (15,8% vs. 7,4%, $p=0,19$). Os doentes com recorrência de FA apresentaram um prognóstico significativamente pior (47,4% versus 23,7%; $p=0,04$), principalmente devido ao aumento das hospitalizações por insuficiência cardíaca.

Conclusões: Em doentes com um primeiro episódio de FA paroxística durante o EAM, a taxa de recorrência em um ano é relativamente baixa (9,1%), mas a recorrência de FA está associada a um prognóstico significativamente pior, principalmente devido ao aumento das hospitalizações por insuficiência cardíaca.

© 2025 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide,¹ and its occurrence in the setting of acute myocardial infarction (AMI) may impact prognosis. Although the prevalence of AF during AMI can reach up to 21%,² data on new-onset AF (NOAF) in this context remain limited, and its long-term impact is not well understood. These patients are particularly complex, since both conditions confer an elevated risk of thromboembolic events, which may lead to ischemic complications. Furthermore, the use of antiplatelet and anticoagulant therapies, which are necessary to manage this risk, can exacerbate the likelihood of hemorrhagic complications.^{1,3}

Several studies have reported a significant increase in mortality, heart failure (HF) hospitalization, and clinically relevant bleeding in patients with AMI and AF compared to those without AF.^{4,5} However, data specifically on NOAF in the context of AMI are limited and sometimes contradictory.^{2,4,6-11} Some authors suggest that NOAF may be transient and self-limiting,¹² which makes the long-term antithrombotic management of these patients controversial.

The introduction of direct oral anticoagulants (DOACs) has improved the management of embolic risk in AF patients. However, anticoagulant therapy –even with the safer profiles of DOACs– carries a significant risk of bleeding, which can have consequences comparable to recurrent ischemic events in terms of morbidity, mortality, and quality of life.¹³

While several randomized trials have evaluated anticoagulant and antiplatelet strategies in patients with a prior history of AF and AMI,¹⁴⁻¹⁸ there is limited evidence on how to manage patients who develop AF for the first time during hospitalization for acute coronary syndrome (ACS).

This paucity of robust evidence is reflected in current clinical guidelines, where recommendations for antithrombotic management in this setting carry a weak level of evidence (IIaC).¹

Objectives

The primary objective of this study was to evaluate the AF recurrence within the first year after discharge in patients with AMI who experienced a first episode of paroxysmal AF. For this study, the 'AF recurrence group' refers to patients who experienced a recurrence of AF during follow-up, while the 'non-AF recurrence group' refers to those who did not. To enhance readability, these groups will be referred to as the 'AF group' and 'non-AF group' from this point onward.

Secondary objectives include comparisons between the AF group and the non-AF group in terms of all-cause mortality, cardiovascular mortality, and a composite endpoint comprising HF hospitalization new ACS, new revascularization, stroke, and major bleeding according to the BARC criteria (see [S1. Secondary objectives](#)).¹⁹ These outcomes were chosen based on prior evidence indicating their relevance in the prognosis of patients with AF and AMI.^{4,5,8,20}

Methods

Patients and study design

A retrospective observational cohort study was conducted including consecutive patients admitted to the Cardiovascular Critical Care Unit (CCCU) of a tertiary care center from December 2011 to May 2021 with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) diagnosis who developed a first episode of paroxysmal AF during hospitalization.

Atrial fibrillation was defined according to current clinical practice guidelines¹ as documented by a standard 12-lead electrocardiogram (ECG) or a single-lead ECG tracing more than 30 seconds showing a cardiac rhythm with indiscernible P waves followed by irregular RR intervals. Paroxysmal AF was defined as AF that reverted spontaneously or required intervention within the first seven days after diagnosis.¹ Myocardial infarction was diagnosed by the attending physician according to current guidelines,^{21,22} based on evidence of myocardial damage (elevated cardiac troponin levels >99th percentile of the upper reference limit), with evidence of necrosis in a clinical context consistent with myocardial ischemia. No restrictions were made regarding the type of AMI including types 1–5 as defined by the Universal Definition of Myocardial Infarction.²³ Coronary anatomy was assessed using diagnostic coronary angiography, and the number of diseased vessels and treated vessels was recorded. Complete revascularization was defined as the treatment of all vessels with a diameter >2 mm and stenosis >70%, or >50% in the case of the left main coronary artery.

Exclusion criteria included patients with a history of prior AF (paroxysmal, permanent, or persistent, even if they presented with sinus rhythm at admission), those who remained in AF at the time of discharge, and those for whom one-year follow-up was not possible. This included patients who died during hospitalization and those who were treated in another healthcare system, as their medical records could not be reliably followed.

Demographic, laboratory, and echocardiographic data, along with interventional and pharmacological treatments during hospitalization and at discharge, were collected. All variables are defined in the supplementary material (see [S2. Variable definitions](#)). A minimum follow-up of one year from the date of hospital discharge was conducted by reviewing patients' medical records through the healthcare information system of the Castilla-La Mancha Health Service (SESCAM).

Statistical analysis

Categorical variables were expressed as numbers and percentages. Quantitative variables were expressed as median and interquartile range (IQR 25–75%). Normal distribution of quantitative variables was assessed using the Shapiro–Wilk test. Categorical variables were compared between groups using the χ^2 test or Fisher's exact test, as appropriate. For normally distributed continuous variables, comparisons were made using Student's t-test, while the Mann–Whitney U test was used for non-normally distributed variables. Com-




Figure 1 Flow chart. Flow of the patients included in the study.

AF: atrial fibrillation; AMI: acute myocardial infarction.

parisons of continuous variables across independent groups were conducted using analysis of variance with Bonferroni correction for multiple comparisons. A two-sided p-value <0.05 was considered statistically significant. Survival outcomes were analyzed using Kaplan–Meier survival curves and Cox proportional hazards regression.

Multivariate regression analysis was performed, including variables related to the index event as reported in the literature,^{6,24} as well as those variables that showed p<0.2 in the bivariate analysis. An additional regression analysis powered by bootstrap technique on 1000 samples was performed ad hoc. All statistical analyses were performed using the Statistical Package for the Social Sciences software (SPSS v. 23.0 for Windows, SPSS Inc., Chicago, IL, USA). This article follows the STROBE recommendations²⁵ for reporting observational studies.

Ethics

The study was conducted in accordance with the principles of the Declaration of Helsinki and good clinical practice guidelines. It was approved by the hospital's Ethics Committee, which granted an exemption from the requirement to obtain informed consent from patients.

Results

Between December 2011 and May 2021, a total of 5291 patients were admitted to the CCCU, of whom 3651 had a diagnosis of AMI. Among these, 269 patients with previous AF were excluded, leaving 3382 patients. From these, 354 developed a first episode of AF (NOAF). After excluding patients with AF at discharge (n=87), in-hospital death (n=33), and those who were expected to be lost to follow-up due to being part of a different healthcare system (n=25), a total of 209 patients were included in the final analysis

Table 1 Baseline characteristics of the patients according to main objective.

Characteristic	Global Median [Q1–Q3], n (%)	Non-AF Median [Q1–Q3], n (%)	AF Median [Q1–Q3], n (%)	p
Age, y	74 [64–80]	74 [64–81]	66 [62–76.5]	0.14
Male	146 (69.9)	134 (70.5)	12 (63.2)	0.60
Hypertension	154 (73.7)	141 (74.2)	13 (68.4)	0.59
Diabetes	72 (34.4)	68 (35.8)	4 (21.1)	0.31
HbA1ac ^a	6 [5.6–6.9]	6 [5.6–6.9]	6.2 [5.7–6.8]	0.80
Dyslipidemia	116 (55.5)	107 (56.3)	9 (47.4)	0.31
Smoker	53 (25.4)	48 (25.3)	5 (26.4)	0.28
Former smoker	46 (22.0)	43 (22.6)	3 (15.8)	
Coronary artery disease	27 (12.9)	25 (13.2)	2 (10.5)	0.48
Cerebral vascular disease	14 (6.7)	13 (6.8)	1 (5.3)	0.92
Peripheral vascular disease	13 (6.2)	12 (6.3)	1 (5.3)	0.49
Alcohol	11 (5.3)	9 (4.7)	2 (10.5)	0.74
Creatinine (mg/dL)	1 [0.81–1.27]	1 [0.82–1.27]	1 [0.79–1.23]	0.97
eGFR CKD-EPI (mL/min/1.73 m ²)	60 [50–75]	60 [50–75]	60 [55.7–73]	0.86
Glucose ^b (mg/dL)	165 [124–221]	166 [126–222]	147 [116–187]	0.21
Hemoglobin (g/dL)	13.6 [12.7–15.1]	13.6 [12.6–15.1]	13.9 [12.8–15.9]	0.42
LDL ^c (mg/dL)	92 [70.5–116]	92 [67–116]	92.5 [82–112]	0.39
HDL ^d (mg/dL)	43 [37–53]	43.5 [37–54]	41.5 [37–48]	0.41
CHA ₂ DS ₂ -VASC	3 [2–4]	3 [2–4]	2 [1–4]	0.12
Hospital stay (days)	9 [6–13]	9 [6–13]	9 [6.5–12.5]	0.83

^a n=194 patients.^b n=203 patients.^c n=200 patients.^d n=200.

Rest of the parameters were analyzed over total n=209.

(Figure 1). Of these, 69.9% (146) were male, with a median age of 74 years [IQR 64–80].

Regarding the primary objective, 19 patients, 9.1% (confidence interval [CI] 5.2–13.0) presented a new episode of AF, of which 13 (68.4%) were paroxysmal. The median time to AF recurrence was 84 days [IQR 28–158] (S3. Kaplan–Meier analysis for AF recurrence). The clinical characteristics, ischemic event features, and treatments are detailed in Tables 1–3. Coronary angiography was performed in 98.6% of patients and percutaneous coronary intervention was the preferred revascularization strategy in both groups.

Within one year of follow-up, 17 patients (8.1%) died, including 14 (7.4%) in the non-AF group and 3 (15.8%) in the AF group (p=0.19). Cardiovascular mortality was 3.8% (8 patients), with no significant differences between groups (p=0.35) (Figure 2). Cardiovascular deaths were primarily due to HF (4 patients) and sudden cardiac death (4 patients), while non-cardiovascular causes included infections (4 patients), cancer (4 patients), and pulmonary embolism (1 patient). Cox regression and other survival analyses showed no statistically significant differences in mortality (Figure 3). The Breslow and Tarone-Ware tests were also applied to detect significant differences at the beginning or end of the curves, but did not provide significant results.

Regarding major adverse cardiovascular events, 25.8% (54 patients) experienced at least one event. Stratification by AF recurrence showed that 47.4% of patients in the AF group had a cardiovascular event within the first

year, compared to 23.7% in the non-AF group (p=0.003) (Figure 4).

Multivariate regression analysis identified a potential protective effect of angiotensin-converting enzyme inhibitors (ACEIs) (b=−2.82; p=0.02) on AF recurrence (S4. Regression analysis). Additional ad hoc analysis using the bootstrap technique to artificially increase the sample size suggested a relationship between diabetes and AF recurrence (b=1.47; p=0.044), as well as protective effects of ACEIs and mineralocorticoid receptor blockers (MRBs) (b=−2.77; p=0.002 and b=−1.94; p=0.047, respectively) (S5. Regression analysis with bootstrapping over 1000 samples).

Discussion

The main findings of our study can be summarized as follows: (1) prevalence of NOAF in the context of AMI in this cohort is approximately 10%; (2) patients with paroxysmal AF (sinus rhythm at discharge) experienced recurrence of around 10% during the first year; (3) AF recurrence was associated with worse prognosis within one year of discharge.

(1) Prevalence of new onset atrial fibrillation in the context of acute myocardial infarction is approximately 10%

The relationship between AF and AMI has been widely studied due to the high prevalence of both conditions and their

Table 2 Characteristics related to ischemic event and echocardiographic parameters according to main objective.

	Global Median [Q1-Q3], n (%)	Non-AF Median [Q1-Q3], n (%)	AF Median [Q1-Q3], n (%)	p
Ischemic event characteristics				
LVEF (%)	45 [35–55]	45 [35–55]	50 [32.5–60]	0.48
STEMI	144 (68.9)	135 (71.1)	9 (47.4)	0.05
NSTEMI	65 (31.1)	55 (29.0)	10 (52.6)	
Killip class				
- I	76 (36.4)	67 (35.3)	9 (47.4)	0.43
- II	72 (34.4)	68 (35.8)	4 (21.1)	
- III	20 (9.6)	17 (8.9)	3 (15.8)	
- IV	41 (19.6)	38 (20.0)	3 (15.8)	
Diagnostic coronariography	206 (98.6%)	187 (98.4)	19 (100.0)	0.58
Number of diseased vessels	1.5 [1–2]	2 [1–2]	1 [1–2]	0.09
PCI	170 (90.4)	156 (83.0)	14 (87.5)	0.91
CABG	9 (4.8)	8 (4.3)	1 (6.3)	0.60
Complete revascularization	113 (63.1)	103 (62.8)	10 (66.7)	0.77
Creatinine kinase peak (U/L)	1140 [473–2730]	1151 [473–2730]	1122 [510.4–2485.5]	0.99
hsTnT peak (ng/L)	2966 [1172–6551]	2988.5 [1201–6430]	2338 [899–10 000]	0.77
Echocardiographic parameter				
LA (AP diameter, mm)	40 [36–43]	40 [36–43]	40 [38–45]	0.40
Mitral regurgitation (baseline)				
- No	35 (16.7)	33 (17.4)	2 (10.5)	0.41
- Mild	107 (51.2)	98 (51.6)	9 (47.4)	
- Moderate	47 (22.5)	40 (21.1)	7 (36.8)	
- Severe	20 (9.6)	19 (10.0)	1 (5.2)	
Mitral regurgitation (follow-up)				
- No	36 (18.9)	33 (19.3)	3 (15.8)	0.44
- Mild	112 (58.9)	103 (60.2)	9 (47.4)	
- Moderate	35 (18.4)	29 (19.9)	6 (31.6)	
- Severe	7 (3.7)	6 (3.5)	1 (5.2)	
LVEF % (follow-up)	50 [45–60]	50 [45–60]	50 [37.5–60]	0.51

AP: anteroposterior; CABG: coronary artery bypass grafting; hsTnT: high-sensitivity T troponin; LA: left atrial; LVEF: left ventricle ejection fraction; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.




Figure 2 Mortality outcomes. All-cause mortality, cardiovascular and non-cardiovascular mortality according to main objective (left) and Kaplan–Meier survival analysis (right). AF: atrial fibrillation.

Table 3 Drug treatment according to main objective.

Treatment	Global n (%)	Non-AF n (%)	AF n (%)	p
ACEI	148 (70.8)	131 (69.0)	17 (89.5)	0.07
ARB	23 (11.0)	21 (11.1)	2 (10.5)	0.94
Spironolactone	39 (18.7)	36 (19.0)	3 (15.8)	0.74
Furosemide	133 (63.6)	122 (64.2)	11 (57.9)	0.62
Betablockers	161 (77.0)	146 (76.8)	15 (79.0)	0.84
Amiodarone	151 (72.2)	137 (72.1)	14 (73.7)	1
Estatine	209 (100)	190 (100)	19 (100)	
Vasopressor drugs	71 (34)	66 (34.7)	5 (26.0)	0.61
Antiplatelet drug	Global n (%)	Non-AF n (%)	AF n (%)	p
ASA	208 (99.5)	189 (99.5)	19 (100)	0.75
Clopidogrel	174 (83.3)	160 (84.2)	14 (73.7)	0.24
Prasugrel	38 (18.2)	33 (17.4)	5 (26.3)	0.34
Ticagrelor	28 (13.4)	24 (12.6)	4 (21.1)	0.30
Anticoagulant	Global n (%)	Non-AF n (%)	AF n (%)	p
No	132 (63.2)	123 (64.7)	9 (47.4)	0.60
Dabigatran	12 (5.7)	10 (5.3)	2 (10.5)	
Apixaban	30 (14.4)	26 (13.7)	4 (21.1)	
Rivaroxaban	4 (1.9)	3 (1.6)	1 (5.3)	
Edoxaban	1 (0.5)	1 (0.5)	0	
VKA	30 (14.4)	27 (14.2)	3 (15.89)	

ACEI: angiotensin-converting enzyme inhibitors; blockers; ARB: angiotensin receptor blocker; ASA: acetylsalicylic acid; VKA: vitamin K antagonist.

significant clinical and socioeconomic impact.^{8,26,27} However, data on NOAF are more limited. The prevalence of NOAF in the context of AMI in our cohort was 10.5% (354 patients who developed a first episode of AF during hospitalization out of 3382 patients without a prior history of AF). This finding is similar to previous studies such as the RIMA registry (8.8%) and Batra et al. (7.6%).^{9,10} A key distinction in our study is the inclusion of both STEMI and NSTEMI patients, whereas previous studies often focused solely on STEMI. Furthermore, we excluded other supraventricular arrhythmias, ensuring that our analysis was specific to NOAF. Additionally, we provided information on patients' heart rhythm at discharge, finding that most were cardioverted during hospitalization (spontaneously or actively), with 24.6% remaining in AF at discharge. These findings are consistent with other studies, while also offering additional insights into rhythm management during hospitalization.

(2) Patients with paroxysmal atrial fibrillation (sinus rhythm at discharge) present recurrence near to 10% within one year

To our knowledge, this is the first study specifically analyzing the recurrence of paroxysmal AF in the context of AMI. We observed a recurrence rate of 9.1% during the first year. Although continuous electrocardiographic monitoring was not used –which could lead to missed self-limiting arrhythmic episodes– our results provide valuable insights into the

clinical course of NOAF following AMI. It is well established that acute ischemic events can act as triggers for AF through mechanisms such as atrial ischemia, increased left ventricular filling pressures, and subsequent atrial dilation.⁶ These factors may resolve after the acute phase, potentially preventing long-term structural damage, which could explain why many patients remain in sinus rhythm during follow-up. This recurrence raises important questions about the need for long-term anticoagulation in patients who maintain sinus rhythm, especially since most of these patients receive dual antiplatelet therapy for 6–12 months post-AMI. Identifying predictors of recurrence is crucial to guiding early anticoagulation strategies. In our study, multivariate logistic regression suggested a protective effect of ACEIs on AF recurrence. Given the limitations of our sample size, a secondary analysis using bootstrapping was performed, which further suggested an association between diabetes and AF recurrence and confirmed the protective effect of ACEIs and ARBs.

It is worth noting that there were no significant differences in baseline characteristics or treatment between patients with and without AF recurrence, which suggests that the perceived cardiovascular risk by the treating physicians was similar across groups. However, changes in clinical practice guidelines over the decade-long study period may have introduced some bias, particularly regarding newer treatments such as neprilysin inhibitors and SGLT2 inhibitors, which were not widely available at the start of the study.




Figure 3 Cox proportional hazards regression. Cox proportional hazards analysis for one-year mortality according to AF recurrence. Curves represent survival probability over time in days for patients without AF recurrence (Non-AF) and with AF recurrence (AF).




Figure 4 Outcomes at 1 year follow-up. Incidence of events at one year follow-up after AMI discharge. Left: overall event rate (%) in the global cohort, non-AF, and AF groups ($p < 0.05$). Right: breakdown by event type—acute coronary syndrome (ACS), new revascularization, heart failure (HF), stroke, and major bleeding—according to group ($p < 0.05$). AF, atrial fibrillation.

(3) Arrhythmic recurrence is associated with worse prognosis in the first year after discharge

A prior history of AF has been historically associated with worse outcomes in patients with AMI, including higher mortality, hospitalizations, and reduced quality of life.^{8,9,20,28} However, NOAF which occurs in response to acute ischemic events may have a different prognosis. Studies have reported conflicting results regarding the impact of NOAF recurrence on outcomes.^{4,9} The CREDO-Kyoto study⁴ reported that both NOAF and chronic AF were associated with increased long-term mortality in AMI patients at five years, regardless of whether sinus rhythm was restored. However, in the RIMA registry,⁹ NOAF was associated with worse cardiovascular outcomes only in the short-term, particularly in the first year following AMI (HR 2.49; 95% CI 1.32–4.67; $p=0.004$).

In our study, AF recurrence during the first year was associated with worse clinical outcomes, especially HF hospitalizations, compared to patients who maintained sinus rhythm. Although we did not find significant differences in overall mortality, likely due to the small sample size, there was a trend toward higher mortality in the AF group. This highlights the need for closer monitoring and management of HF in patients with AF recurrence following AMI.

Larger studies are necessary to confirm the long-term impact of AF recurrence and to determine whether early rhythm control or anticoagulation strategies could improve outcomes in this high-risk group.

Limitations

Our study has certain limitations inherent to its design. Firstly, as a retrospective observational study, the data were limited to the information available in the electronic medical records, which may introduce bias or incomplete data. Additionally, as it was a single-center study, the sample size was restricted, which could limit the ability to achieve statistical significance in some analyses. As such, these results should be interpreted as hypothesis-generating. A prospective multicenter study would be valuable to further investigate the questions raised in this analysis. Moreover, the study spans a ten-year period, during which updates to clinical practice guidelines were made as new evidence emerged. This may have introduced variability in the management of patients over time, potentially affecting the consistency of treatments and outcomes.

Conclusions

Our study provides valuable data on the prevalence of NOAF in the context of AMI over a 10-year period, confirming its frequent occurrence in routine clinical practice. Importantly, we focused on patients discharged in sinus rhythm, a cohort underrepresented in the literature. We found that arrhythmic recurrence occurred in approximately 10% of these patients within the first year. Although cardiovascular, non-cardiovascular, and overall mortality were higher in patients with AF recurrence, statistical significance was not reached likely due to sample size limitations. Nonetheless, these patients had a significantly worse prognosis at

one year, mainly driven by a higher incidence of HF hospitalizations.

Larger multicenter studies are needed to better understand the factors that predispose patients to arrhythmic recurrence and worse outcomes, facilitating closer monitoring and tailored management for high-risk individuals.

Ethical approval

Ethics Committee of the Integrated Care Management of Albacete, study no. 2022-091.

Conflict of interests

The authors have no conflicts of interest to declare.

Appendix A. Supplementary data

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.repc.2024.12.008>.

References

1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2021;42:373–498.
2. Ruddox V, Sandven I, Munkhaugen J, et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2017;24:1555–66.
3. Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a north American perspective: 2021 update. *Circulation*. 2021;143:583–96.
4. Obayashi Y, Shiomi H, Morimoto T, et al. Newly diagnosed atrial fibrillation in acute myocardial infarction. *J Am Heart Assoc*. 2021;10:e021417.
5. Luo J, Xu S, Li H, et al. Long-term impact of new-onset atrial fibrillation complicating acute myocardial infarction on heart failure. *ESC Heart Fail*. 2020;7:2762–72.
6. Belkhouche A, Yao H, Putot A, et al. The multifaceted interplay between atrial fibrillation and myocardial infarction: a review. *J Clin Med*. 2021;10:1–15.
7. Feistritz HJ, Desch S, Zeymer U, et al. Prognostic impact of atrial fibrillation in acute myocardial infarction and cardiogenic shock: results from the CULPRIT-SHOCK Trial. *Circ Cardiovasc Interv*. 2019;12:1–9.
8. Carnicelli AP, Owen R, Pocock SJ, et al. Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. *Open Heart*. 2021;8:e001726.
9. Gourronc Y, Grall S, Ingremeau D, et al. De novo atrial fibrillation as an independent prognostic marker after ST-segment elevation myocardial infarction: results from the RIMA registry. *J Cardiol*. 2019;74:123–9.
10. Batra G, Svennblad B, Held C, et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. *Heart*. 2016;102:926–33.
11. Pyka L, Gasior M. Atrial fibrillation and myocardial infarction – in constant need for new data. *Eur J Prev Cardiol*. 2019;26:1370–2.

12. Wang EY, Hulme OL, Khurshid S, et al. Initial precipitants and recurrence of atrial fibrillation. *Circ Arrhythm Electrophysiol.* 2020;13:e007716.
13. De Caterina R, Agewall S, Andreotti F, et al. Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. *Eur Heart J.* 2022;43:3512–27.
14. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. *Lancet.* 2019;394:1335–43.
15. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *NEJM.* 2017;377:1513–24.
16. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. *NEJM.* 2016;375:2423–34.
17. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *NEJM.* 2019;380:1509–24.
18. Escobar C, Martí-Almor J, Pérez Cabeza A, et al. Direct oral anticoagulants versus vitamin K antagonists in real-life patients with atrial fibrillation. A systematic review and meta-analysis. *Rev Esp Cardiol.* 2019;72:305–16.
19. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. *Circulation.* 2011;123:2736–47.
20. Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. *Circulation.* 2011;123:2094–100.
21. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J.* 2018;39:119–77.
22. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J.* 2021;42:1289–367.
23. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). *Circulation.* 2018;138:e618–51.
24. Schnabel RB, Yin X, Gona P, et al. 50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet.* 2015;386:154–62.
25. Von Elm E, Altman DG, Egger M, et al. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol.* 2008;61:344–9.
26. Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. *Circ Res.* 2020;127:4–20.
27. El-Shetry M, Mahfouz R, Frere AF, et al. The interplay between atrial fibrillation and acute myocardial infarction. *Br J Hosp Med.* 2021;82:1–9.
28. Jortveit J, Pripp AH, Langørgen J, et al. Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. *Eur J Prev Cardiol.* 2019;26:1373–82.